Abstract 16405: Prevention of HeartMate II Pump Thrombosis - Recommendations and Preliminary Observations From the PREVENT Study
Introduction and hypothesis: Recent data have indicated an increase in the rate of early, confirmed pump thrombosis of the HeartMate II (HMII) left ventricular assist device. Factors related to this increase were not known, but one of the hypotheses was change in clinical management over time. The PREVENT (PREVENtion of Heartmate II Pump Thrombosis through Clinical Management) study was designed to evaluate the impact of clinical practices developed to reduce the risk of HMII pump thrombosis.
Methods: PREVENT is a prospective, multi-center, single-arm, non-randomized study of up to 300 patients at up to 25 sites. Patient and pump management, including implant technique, anticoagulation, and pump settings are guided by protocol (Table 1). Primary endpoint is incidence of confirmed pump thrombosis at 3 months, with a total follow-up of 6 months. Presented here are the preliminary results from the first 100 subjects enrolled.
Results: Median age was 61 years [25-79], 87% were male, and 79% were destination therapy. At implant, 9% were in INTERMACS Profile1, 68% Profiles 2-3, and 22% Profiles 4-7. Preliminary analysis of 90-day outcomes demonstrated an incidence of 1% for confirmed and 2% for suspected thrombosis with a 38% incidence of INTERMACS-defined bleeding. Adherence to the protocol recommendations was as follows: 91% of the pumps were anchored, 97% of the patients were bridged with heparin, median pump speed at 1 month was 9190 [range: 8400-10000], with 93% of the patients having a pump speed > 8600, and 78% of the patients having pump speeds > 9000. Median INR per patient was 2.2 [IQR: 2.0-2.4]. Overall Kaplan-Meier survival was 93%.
Conclusions: Preliminary results are encouraging and suggest good adherence to the PREVENT protocol and low rates of pump thrombosis without a resultant increase in bleeding complications. Overall survival after HM II implantation remains excellent.
Author Disclosures: S. Emani: Research Grant; Modest; Thoratec. Consultant/Advisory Board; Modest; Thoratec, St. Jude Medical. M. Keebler: None. J.M. Ransom: None. A. Kilic: None. G. Egnacyzk: None. R. Gallegos: None. P. Mather: None. J. Stulak: None. I. Gregoric: None. J. Katz: None. C.T. Klodell: None. N. Uriel: None. J.B. O’Connell: Employment; Significant; Thoratec Corporation. D. Farrar: Employment; Significant; Thoratec Corporation. K. Sundareswaran: Employment; Significant; Thoratec Corporation. S. Maltais: None.
- © 2015 by American Heart Association, Inc.